Trial reportBMC neurology2013
The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen.
Trial report in BMC neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03011476 (Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease Characterized by Postural Instability and Gait Disturbance), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease Characterized by Postural Instability and Gait Disturbance
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Interventions for preventing falls in Parkinson's disease.The Cochrane database of systematic reviews · 2022Pooled it
- Trial
- Effect of rivastigmine on mobility of patients with higher-level gait disorder: a pilot exploratory study.Drugs in R&D · 2014Trial
- Neurotransmitter Systems Underlying Freezing of Gait (FOG) in Parkinson's Disease.The European journal of neuroscience · 2026Review
- Prevention of Falls in Parkinson's Disease: Guidelines and Gaps.Movement disorders clinical practice · 2023Review
- Predicting Fall Counts Using Wearable Sensors: A Novel Digital Biomarker for Parkinson's Disease.Sensors (Basel, Switzerland) · 2021Article
- The Association Between Frailty and Parkinson's Disease in the ReSPOnD Trial.Canadian geriatrics journal : CGJ · 2021Article
- Correlations between Motor Symptoms across Different Motor Tasks, QuantifiedFrontiers in neurology · 2017Article
- Pharmacological treatment in Parkinson's disease: Effects on gait.Parkinsonism & related disorders · 2016Review
- Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.International journal of molecular sciences · 2016Review
- Gait Disorder in a Cohort of Patients With Mild and Moderate Alzheimer's Disease.American journal of Alzheimer's disease and other dementias · 2016Article
- Comparison of Test Your Memory and Montreal Cognitive Assessment Measures in Parkinson's Disease.Parkinson's disease · 2016Article
- Machine learning classification of medication adherence in patients with movement disorders using non-wearable sensors.Computers in biology and medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundGait impairment is common in people with Parkinson's disease. There is a lack of effective interventions to target this debilitating complication and therefore a need to identify new therapeutic options. An underlying cholinergic deficit contributes to both the gait and cognitive dysfunction seen in Parkinson's disease. The combined impact of both impairments can be assessed in gait tasks performed with concomitant cognitive tasks. The aim of this trial is to evaluate the impact of a cholinesterase inhibitor on cognitive function and gait performance in people with established Parkinson's disease. METHODS/
designThis is a single centre, double-blind, randomised placebo-controlled trial in 130 people with Hoehn and Yahr stage 2-3 idiopathic Parkinson's disease who have fallen in the past year. Participants will be randomised to two groups, receiving either rivastigmine capsules or identical placebo capsules for 8 months. Assessment will be undertaken at baseline and at the end of medication prescription (i.e. 8 months) with participants remaining enrolled in the trial for a further 4 months to monitor for falls and adverse events. The primary outcome is step time variability, assessed with and without the addition of concurrent cognitive tasks. Secondary outcomes will include other gait parameters, sensorimotor and balance performances, cognitive indices, falls and fall related injury, fear of falling, Parkinson's symptoms and data pertaining to possible harms. DISCUSSION: This randomised controlled trial will examine the effect of cholinesterase inhibitor therapy on gait, balance and falls in Parkinson's disease. If effective, it would offer a new therapeutic option to ameliorating gait and cognitive deficits in a population at high risk of falls.
trial registrationISRCTN19880883, UTN U1111-1124-0244.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.